3 results
the Sponsor aims to investigate if JDQ443 will stop abnormal cell growth related to the marker KRAS G12C mutation in patients with NSCLC whose tumors have specific characteristics, such as the presence of a KRAS G12C mutation, as well as the…
1. The primary efficacy objective is to evaluate whether rivaroxaban, in doses of 10 mg or 20 mg, is superior to ASA 100 mg in the prevention of the primary efficacy outcome (i.e. fatal or non-fatal symptomatic recurrent venous thromboembolism).2.…
Within the proposed study design it is possible to answer more study questions within the same population and within the same timeframe without adding much burden to the study participants. measurements and analyses will be performed both during a…